FDA approves third oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor

FDA approves third oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor

FDA also approves drug for second indication in a type of lung cancer

Silver Spring, MD (STL.News) – The U.S. Food and Drug Administration today granted accelerated approval to Rozlytrek (entrectinib), a treatment for adult and adolescent patients whose cancers have the specific genetic defect, NTRK (neurotrophic tyrosine receptor kinase) gene fusion and for whom there are no effective treatments.

“We are in an exciting era of innovation in cancer treatment as we continue to see development in tissue agnostic therapies, which have the potential to transform cancer treatment. 

Continue reading FDA approves third oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor at STL.News.